MJV 101

Drug Profile

MJV 101

Alternative Names: Cancer vaccine - Mojave Therapeutics; Melanoma vaccine-Mojave Therapeutics; MJV-101

Latest Information Update: 18 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mojave Therapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 15 Apr 2003 Data from a media release have been added to the Cancer therapeutic trials section and overview
  • 04 Sep 2002 Mojave expects to initiate a phase I/II trial in patients with prostate cancer pending the results of the melanoma trial
  • 23 Apr 2002 Phase-I/II clinical trials in Malignant melanoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top